SCHEMBL6822871

SCHEMBL6822871

CC(C)[Si](OCc1cc(Cl)ccc1I)(C(C)C)C(C)C

nearest known ligand 0.32

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 3/20 0.32
GAA P10253 1/20 0.31
SLC6A4 P31645 3/20 0.31
HTR2C P28335 2/20 0.31
HTR2A P28223 1/20 0.31
MEN1 O00255 1/20 0.31
SLC22A1 O15245 1/20 0.31
USP2 O75604 1/20 0.31
LMNA P02545 1/20 0.31
HSP90AA1 P07900 1/20 0.31
CYP3A4 P08684 1/20 0.31
MAPT P10636 1/20 0.31
HSPD1 P10809 1/20 0.31
HSPA5 P11021 1/20 0.31
HPGD P15428 1/20 0.31
ALOX15 P16050 1/20 0.31
ALOX12 P18054 1/20 0.31
CASP1 P29466 1/20 0.31
HTT P42858 1/20 0.31
BLM P54132 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6818762 0.81 NOS3 (0.40) IDO1GAASLC6A4HTR2CHTR2A
SCHEMBL5605178 0.80 IDO1 (0.53) IDO1GAAMEN1LMNACYP3A4
SCHEMBL6816069 0.78 ENPP2 (0.35) IDO1GAASLC6A4HTR2CHTR2A
SCHEMBL16497034 0.77 PYCR1 (0.43) IDO1GAASLC6A4MEN1LMNA
SCHEMBL28603541 0.75 HTT (0.38) IDO1SLC6A4HTR2AMEN1SLC22A1
SCHEMBL15308128 0.71 SLC5A2 (0.38)
SCHEMBL6820091 0.71 NOTUM (0.40)
SCHEMBL6819640 0.71 PIEZO1 (0.38) SLC6A4MEN1LMNAMAPTKMT2A
SCHEMBL6925341 0.70 IDO1 (0.34) IDO1GAASLC6A4
SCHEMBL18797233 0.70 SMN1; SMN2 (0.38) SLC6A4LMNAHPGDHTTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004032834-A2 THROMBIN INHIBITORS MERCK & CO., INC. (US) 2004-04-22 WO disclosed
US-6515011-B2 Anticoagulants MERCK & CO., INC. 2003-02-04 US disclosed
US-20020119992-A1 Thrombin inhibitors MERCK & CO., INC. 2002-08-29 US disclosed
WO-2002050056-A1 BENZYLAMINE DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS MERCK & CO., INC. (US) 2002-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020119992-A1 Thrombin inhibitors SERPINC1, F2, TFPI IDO1 2641/4885GAA 4559/4885SLC6A4 4339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.